242 related articles for article (PubMed ID: 22817711)
1. Potential neuroprotective strategies against tauopathy.
Wheeler JM; Guthrie CR; Kraemer BC
Biochem Soc Trans; 2012 Aug; 40(4):656-60. PubMed ID: 22817711
[TBL] [Abstract][Full Text] [Related]
2. MSUT2 is a determinant of susceptibility to tau neurotoxicity.
Guthrie CR; Greenup L; Leverenz JB; Kraemer BC
Hum Mol Genet; 2011 May; 20(10):1989-99. PubMed ID: 21355046
[TBL] [Abstract][Full Text] [Related]
3. The role of MSUT-2 in tau neurotoxicity: a target for neuroprotection in tauopathy?
Wheeler JM; Guthrie CR; Kraemer BC
Biochem Soc Trans; 2010 Aug; 38(4):973-6. PubMed ID: 20658987
[TBL] [Abstract][Full Text] [Related]
4. AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery.
Baker JD; Uhrich RL; Strovas TJ; Saxton AD; Kraemer BC
SLAS Discov; 2021 Mar; 26(3):400-409. PubMed ID: 32981422
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity.
McCormick AV; Wheeler JM; Guthrie CR; Liachko NF; Kraemer BC
Biol Psychiatry; 2013 Mar; 73(5):464-71. PubMed ID: 23140663
[TBL] [Abstract][Full Text] [Related]
6. SPOP loss of function protects against tauopathy.
Eck RJ; Kow RL; Black AH; Liachko NF; Kraemer BC
Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2207250120. PubMed ID: 36574656
[TBL] [Abstract][Full Text] [Related]
7. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.
Kraemer BC; Zhang B; Leverenz JB; Thomas JH; Trojanowski JQ; Schellenberg GD
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9980-5. PubMed ID: 12872001
[TBL] [Abstract][Full Text] [Related]
8. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
9. Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).
Gibbons GS; Kim SJ; Robinson JL; Changolkar L; Irwin DJ; Shaw LM; Lee VM; Trojanowski JQ
Acta Neuropathol Commun; 2019 Mar; 7(1):34. PubMed ID: 30832741
[TBL] [Abstract][Full Text] [Related]
10.
Pir GJ; Choudhary B; Mandelkow E
FASEB J; 2017 Dec; 31(12):5137-5148. PubMed ID: 29191965
[TBL] [Abstract][Full Text] [Related]
11. Glutamatergic nervous system degeneration in a C. elegans Tau
Choudhary B; Mandelkow E; Mandelkow EM; Pir GJ
Neurobiol Dis; 2018 Sep; 117():189-202. PubMed ID: 29894752
[TBL] [Abstract][Full Text] [Related]
12. Loss of aly/ALYREF suppresses toxicity in both tau and TDP-43 models of neurodegeneration.
Kow RL; Black AH; Saxton AD; Liachko NF; Kraemer BC
Geroscience; 2022 Apr; 44(2):747-761. PubMed ID: 35122183
[TBL] [Abstract][Full Text] [Related]
13. DOPA Decarboxylase Modulates Tau Toxicity.
Kow RL; Sikkema C; Wheeler JM; Wilkinson CW; Kraemer BC
Biol Psychiatry; 2018 Mar; 83(5):438-446. PubMed ID: 28751068
[TBL] [Abstract][Full Text] [Related]
14. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.
Fatouros C; Pir GJ; Biernat J; Koushika SP; Mandelkow E; Mandelkow EM; Schmidt E; Baumeister R
Hum Mol Genet; 2012 Aug; 21(16):3587-603. PubMed ID: 22611162
[TBL] [Abstract][Full Text] [Related]
16. Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain.
Wheeler JM; McMillan P; Strovas TJ; Liachko NF; Amlie-Wolf A; Kow RL; Klein RL; Szot P; Robinson L; Guthrie C; Saxton A; Kanaan NM; Raskind M; Peskind E; Trojanowski JQ; Lee VMY; Wang LS; Keene CD; Bird T; Schellenberg GD; Kraemer B
Sci Transl Med; 2019 Dec; 11(523):. PubMed ID: 31852801
[TBL] [Abstract][Full Text] [Related]
17. Distinct Poly(A) nucleases have differential impact on sut-2 dependent tauopathy phenotypes.
Kow RL; Strovas TJ; McMillan PJ; Jacobi AM; Behlke MA; Saxton AD; Latimer CS; Keene CD; Kraemer BC
Neurobiol Dis; 2021 Jan; 147():105148. PubMed ID: 33184027
[TBL] [Abstract][Full Text] [Related]
18. Generation of a human induced pluripotent stem cell-based model for tauopathies combining three microtubule-associated protein TAU mutations which displays several phenotypes linked to neurodegeneration.
García-León JA; Cabrera-Socorro A; Eggermont K; Swijsen A; Terryn J; Fazal R; Nami F; Ordovás L; Quiles A; Lluis F; Serneels L; Wierda K; Sierksma A; Kreir M; Pestana F; Van Damme P; De Strooper B; Thorrez L; Ebneth A; Verfaillie CM
Alzheimers Dement; 2018 Oct; 14(10):1261-1280. PubMed ID: 30036493
[TBL] [Abstract][Full Text] [Related]
19. Neuron-selective toxicity of tau peptide in a cell culture model of neurodegenerative tauopathy: essential role for aggregation in neurotoxicity.
Zhao K; Ippolito G; Wang L; Price V; Kim MH; Cornwell G; Fulenchek S; Breen GA; Goux WJ; D'Mello SR
J Neurosci Res; 2010 Nov; 88(15):3399-413. PubMed ID: 20882568
[TBL] [Abstract][Full Text] [Related]
20. V363I and V363A mutated tau affect aggregation and neuronal dysfunction differently in C. elegans.
Morelli F; Romeo M; Barzago MM; Bolis M; Mattioni D; Rossi G; Tagliavini F; Bastone A; Salmona M; Diomede L
Neurobiol Dis; 2018 Sep; 117():226-234. PubMed ID: 29936232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
